RESUMEN
HLA-A*02:548 differs from A*02:01:01:01 by one nucleotide at position 367T > C resulting in histidine at codon 99.
Asunto(s)
Alelos , Sustitución de Aminoácidos , Antígeno HLA-A2/genética , Polimorfismo de Nucleótido Simple , Donantes de Tejidos , Secuencia de Bases , Trasplante de Médula Ósea , Codón , Exones , Expresión Génica , Antígeno HLA-A2/inmunología , Prueba de Histocompatibilidad , Humanos , Datos de Secuencia Molecular , Alineación de SecuenciaRESUMEN
HLA-B*35:08:17 differs from B*35:08:01:01 by a single nucleotide change in codon 105 (CCC > CCG).
Asunto(s)
Genes MHC Clase I , Antígenos HLA-B , Humanos , Alelos , Antígenos HLA-B/genética , Codón , Nucleótidos , Análisis de Secuencia de ADNRESUMEN
HLA-DRB1*03:85 differs from HLA-DRB1*03:06 by two nucleotides, position 257 A>T and position 258T>C, resulting in Valine at codon 57.
Asunto(s)
Alelos , Cadenas HLA-DRB1/genética , Secuencia de Bases , Exones/genética , Humanos , Datos de Secuencia Molecular , Alineación de SecuenciaRESUMEN
HLA-C*06:297 differs from C*06:02:01:01 by a single nucleotide change in codon-19 (CCC>TCC).
Asunto(s)
Antígenos HLA-C , Secuenciación de Nucleótidos de Alto Rendimiento , Alelos , Exones/genética , Genes MHC Clase I , Antígenos HLA-C/genética , HumanosRESUMEN
HLA-B*14:58 differs from B*14:02:01 by a polymorphism at position 506 a C instead a G.
Asunto(s)
Alelos , Antígenos HLA-B/genética , Secuencia de Bases , Humanos , Polimorfismo de Nucleótido Simple/genética , Alineación de SecuenciaRESUMEN
DRB1*14:172 homologous to DRB1*14:01 has been found with a variation in 314 A > G.
Asunto(s)
Alelos , Exones , Cadenas HLA-DRB1/genética , Mutación Puntual , Receptores de Trasplantes , Sustitución de Aminoácidos , Secuencia de Bases , Codón/química , Cadenas HLA-DRB1/inmunología , Prueba de Histocompatibilidad/métodos , Humanos , Trasplante de Hígado , Alineación de Secuencia , Análisis de Secuencia de ADNRESUMEN
We report the preliminary results of a study exploring the possibility of collecting circulating progenitor cells (PBSC) with a protocol based on the administration of single doses (4 g/m2) of cyclophosphamide and G-CSF (5 or 10-micrograms/kg) in 9 patients with non Hodgkin's lymphoma. The peak level of CD34+ cells occurred after a median of 10 days (range 8-11), generally coinciding with the median peak level of CFU-GM, with a mean 31.27 fold increase above basal levels. 3 (range 2-5) leukaphereses were required to harvest a median number of 25.1 x 10(4)/kg (8-105) CFU-GM and of 9.4 x 10(6)/kg (1.2-25) CD34+ cells. No difference was recorded between 5 and 10 micrograms/kg of G-CSF in terms of PBSC yield. In transplanted patients, a strong correlation was found between CD34+ cells infused/kg and platelet recovery (r = -0.8, p = 0.002). No toxicity was observed and apheretic procedures were regularly performed outpatiently. Our conclusion is that this protocol is particularly suitable for an outpatient treatment/collection program.